Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …

Simple Summary Prostate cancer remains one of the leading causes of cancer death in men
worldwide. Despite the recent success in the development and clinical application of …

Simple Summary The concept of targeted drug delivery (TDD) represents an innovative and
effective treatment approach, which was developed with an attempt to minimize damage …

Background: PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for
metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu …

The recently presented and published results of the VISION phase III study of 177Lu-
PSMA617 for metastatic castrationresistant prostate cancer (1) are indeed one of the …

The process of bringing a new drug to market is complex and has recently necessitated a
new drug-discovery paradigm for the pharmaceutical industry that is both more efficient and …

This project focuses on the generation and evaluation of functional alternatives to radiometal-
based pharmaceuticals supporting basic research and the in vitro developmental phase …

Abstract Development and testing of prostate-specific membrane antigen (PSMA)-targeting
radionuclide therapy (TRT) for prostate cancer diagnosis and endoradiotherapy have seen …

Dear sir, I just read the two editorials written by Michael Hofman (1) and by Czernim and
Calais (2) commenting on the use of 177Lu–PSMA-617 therapy in patients with metastatic …

I read with interest the recent publication in JNM titled “A guide to ComBat harmonization of
imaging biomarkers in multicenter studies”(1). The work discussed in the article presents …